Organisation paid for research Program year 2025 Source: CMS Open Payments

Ccm Clinical Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$991,602

142 payments

Through program year 2025, Ccm Clinical Research Group LLC is reported as receiving $991,602 in research payments, across 142 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$406,270	83
2024	Research	$277,653	13
2023	Research	$105,550	10
2022	Research	$79,792	10
2021	Research	$56,404	24
2020	Research	$59,433	1
2019	Research	$6,500	1

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $315,068 11 payments
Boehringer Ingelheim International GmbH $311,892 71 payments
Eisai Inc. $276,354 36 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $74,742 3 payments
Boehringer Ingelheim RCV GmbH & Co KG $13,546 21 payments

Studies the money was for Research payments · program years 2019–2025

A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $317,291 27 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $276,354 36 payments
Phase II DRF study of NR2B modulation in MDD $251,041 2 payments
A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $65,933 2 payments
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD $57,076 47 payments
A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $8,809 1 payment
BI 425809 Pivotal efficacy study 1 $7,496 5 payments
Connex 1 $5,326 17 payments
Phase II dose finding trial in monotherapy for MDD $1,035 1 payment
Connex-3 $829 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.